Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Gain Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 24 | 24 | 0 |
| Shares | 1.27M | 1.52M | +247.8K (+19.5%) |
| Value | $5.68M | $4.95M | −$724.5K (−12.8%) |
New holders (2)
Institutions that held Gain Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Simplex Trading, LLC | 8,650 | $28.0K | 0.00% |
| Householder Group Estate & Retirement Specialist, LLC | 2,500 | $8.20K | 0.00% |
Sold out (2)
Institutions that held Gain Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Millennium Management LLC | 12,562 | $56.3K |
| JPMorgan Chase & Co | 6 | $27 |